Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in Predicting Virological Outcomes Over Time

被引:50
作者
Frentz, Dineke [1 ]
Boucher, Charles A. B. [1 ,2 ]
Assel, Matthias [3 ]
De Luca, Andrea [4 ,5 ]
Fabbiani, Massimiliano [4 ]
Incardona, Francesca [6 ]
Libin, Pieter [7 ]
Manca, Nino [8 ]
Mueller, Viktor [9 ]
Nuallain, Breanndan O. [10 ]
Paredes, Roger [11 ]
Prosperi, Mattia [12 ]
Quiros-Roldan, Eugenia [13 ]
Ruiz, Lidia [11 ]
Sloot, Peter M. A. [10 ]
Torti, Carlo [13 ]
Vandamme, Anne-Mieke
Van Laethem, Kristel [15 ]
Zazzi, Maurizio [14 ]
van de Vijver, David A. M. C. [1 ]
机构
[1] Univ Med Ctr Rotterdam, Erasmus MC, Rotterdam, Netherlands
[2] Univ Med Ctr Utrecht, Utrecht, Netherlands
[3] Univ Stuttgart, High Performance Comp Ctr Stuttgart, Stuttgart, Germany
[4] Univ Cattolica Sacro Cuore, Inst Clin Infect Dis, I-00168 Rome, Italy
[5] Univ Hosp Siena, Infect Dis Unit 2, Siena, Italy
[6] Informa SrL, Rome, Italy
[7] MyBioData, Rotselaar, Belgium
[8] Univ Brescia, Sch Med, Inst Microbiol, Brescia, Italy
[9] Eotvos Lorand Univ, Inst Biol, Budapest, Hungary
[10] Univ Amsterdam, Amsterdam, Netherlands
[11] SIDA irsiCaixa, Inst Recerca, Badalona, Spain
[12] Catholic Univ, Clin Infect Dis, Rome, Italy
[13] Univ Brescia, Sch Med, Inst Infect & Trop Dis, Brescia, Italy
[14] Univ Siena, Dept Mol Biol, I-53100 Siena, Italy
[15] Katholieke Univ Leuven, Rega Inst, Leuven, Belgium
来源
PLOS ONE | 2010年 / 5卷 / 07期
关键词
DRUG-RESISTANCE; ANTIRETROVIRAL THERAPY; PROTEASE;
D O I
10.1371/journal.pone.0011505
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Several decision support systems have been developed to interpret HIV-1 drug resistance genotyping results. This study compares the ability of the most commonly used systems (ANRS, Rega, and Stanford's HIVdb) to predict virological outcome at 12, 24, and 48 weeks. Methodology/Principal Findings: Included were 3763 treatment-change episodes (TCEs) for which a HIV-1 genotype was available at the time of changing treatment with at least one follow-up viral load measurement. Genotypic susceptibility scores for the active regimens were calculated using scores defined by each interpretation system. Using logistic regression, we determined the association between the genotypic susceptibility score and proportion of TCEs having an undetectable viral load (<50 copies/ml) at 12 (8-16) weeks (2152 TCEs), 24 (16-32) weeks (2570 TCEs), and 48 (44-52) weeks (1083 TCEs). The Area under the ROC curve was calculated using a 10-fold cross-validation to compare the different interpretation systems regarding the sensitivity and specificity for predicting undetectable viral load. The mean genotypic susceptibility score of the systems was slightly smaller for HIVdb, with 1.92 +/- 1.17, compared to Rega and ANRS, with 2.22 +/- 1.09 and 2.23 +/- 1.05, respectively. However, similar odds ratio's were found for the association between each-unit increase in genotypic susceptibility score and undetectable viral load at week 12; 1.6 [95% confidence interval 1.5-1.7] for HIVdb, 1.7 [1.5-1.8] for ANRS, and 1.7 [1.9-1.6] for Rega. Odds ratio's increased over time, but remained comparable (odds ratio's ranging between 1.9-2.1 at 24 weeks and 1.9-2.2 at 48 weeks). The Area under the curve of the ROC did not differ between the systems at all time points; p = 0.60 at week 12, p = 0.71 at week 24, and p = 0.97 at week 48. Conclusions/Significance: Three commonly used HIV drug resistance interpretation systems ANRS, Rega and HIVdb predict virological response at 12, 24, and 48 weeks, after change of treatment to the same extent.
引用
收藏
页数:9
相关论文
共 20 条
  • [1] Brun-Vézinet F, 2004, ANTIVIR THER, V9, P465
  • [2] Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)
    Cingolani, A
    Antinori, A
    Rizzo, MG
    Murri, R
    Ammassari, A
    Baldini, F
    Di Giambenedetto, S
    Cauda, R
    De Luca, A
    [J]. AIDS, 2002, 16 (03) : 369 - 379
  • [3] Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type I drug resistance
    De Luca, A
    Cingolani, A
    Di Giambenedetto, S
    Trotta, MP
    Baldini, F
    Rizzo, MG
    Bertoli, A
    Liuzzi, G
    Narciso, P
    Murri, R
    Antmassari, A
    Perno, CF
    Antinori, A
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (12) : 1934 - 1943
  • [4] Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial
    Durant, J
    Clevenbergh, P
    Halfon, P
    Delgiudice, P
    Porsin, S
    Simonet, P
    Montagne, N
    Boucher, CAB
    Schapiro, JM
    Dellamonica, P
    [J]. LANCET, 1999, 353 (9171) : 2195 - 2199
  • [5] The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors
    Fox, Zoe V.
    Geretti, Anna Maria
    Kjaer, Jesper
    Dragsted, Ulrik Bak
    Phillips, Andrew N.
    Gerstoft, Jan
    Staszewski, Schlomo
    Clotet, Bonaventura
    von Wyl, Viktor
    Lundgren, Jens D.
    [J]. AIDS, 2007, 21 (15) : 2033 - 2042
  • [6] Hastie T., 2001, ELEMENTS STAT LEARNI
  • [7] Johnson Victoria A, 2008, Top HIV Med, V16, P138
  • [8] Larder B, 2007, ANTIVIR THER, V12, P15
  • [9] Web resources for HIV type 1 genotypic-resistance test interpretation
    Liu, TF
    Shafer, RW
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 42 (11) : 1608 - 1618
  • [10] Impact of drug resistance mutations on virologic response to salvage therapy
    Lorenzi, P
    Opravil, M
    Hirschel, B
    Chave, JP
    Furrer, HJ
    Sax, H
    Perneger, TV
    Perrin, L
    Kaiser, L
    Yerly, S
    [J]. AIDS, 1999, 13 (02) : F17 - F21